The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Great. Thanks, Howard, and we'll give just a second for everyone's video to come back online. Okay. Great. (Operator Instructions) We do have 1
so far which is with the PROPEL update not coming to the back half of the year, what's in the abstract -- what's the abstract for World Lung going
to be now?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay, great. But we should expect that PROPEL update to come at a medical conference as opposed to a press release?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay.
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Got it. And can you elaborate on what response rates you would want to see in each of those PD-L1 expression groups and PROPEL to get
you confident, you have a signal worth pursuing in Phase III?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. We've got another investor question here. It says Nektar is clearly the most advanced company within the next-gen IL-2 landscape.
But can you provide commentary on the emerging IL-2 programs, for example, THOR-707, Zilio, Werewolf, et cetera, and how you expect them to
be positioned relative in that competitive landscape down the road?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. Maybe turning to the Phase III trial in melanoma for BEMPEG, can you help us understand the communication around the ORR-based
interim in that study? If the interim takes place, but it doesn't hit, would you communicate that to The Street? And if it does hit on the interim,
would you stop the study or run it out for PFS? And just how would those scenarios work? I guess, could interim ORR data alone be a basis for
approval?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 11, 2021 / 7:50PM, NKTR.OQ - Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Can you talk about your expectations for ORR and DoR in the pivotal trial for bladder cancer? What do you see as the bar in that setting?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. Time for 1 more question, and there's no more coming in through the portal. So maybe switching to NKTR-262. Following the dose
escalation data and selection of a recommended Phase II dose, what's the timeline to see data from the expansion cohorts for the REVEAL study
that would include antitumor activity? And based on the escalation data, do you have any expectations for what range ORR could fall in?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. Thanks for that. It looks like we're out of time. So thanks, everyone, for tuning in, and thanks to the management team as well.
| 
